MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma.

Zhi-Xia YueTian-Yu XingWen ZhaoQian ZhaoXi-Si WangYan SuChao GaoShu-Guang LiuXiao-Li Ma

Published in: Cancer medicine (2022)

Patients with both MYCN amplification and 1p36LOH had the worst survival rate, indicating an ultra high-risk group. Our results may be applied in clinical practice for accurate risk stratification in future studies.

Keyphrases

bone marrow
high resolution
clinical practice
nucleic acid
squamous cell carcinoma
small cell lung cancer
mesenchymal stem cells
current status